Earlier this month, MedAI announces that it has integrated its three AI-powered drug discovery platforms so as to increase drug candidate efficacy and safety throughout the preclinical research. Previously, the company has released AIDD Platform, CADD Platform, and Experimental Validation Platform, which consist of proprietary hardware, biological, molecular and digital technologies.
"The indispensable role of data analytics, knowledge management and artificial intelligence in early drug discovery has been approved in the past few years. We are looking forward to partnering with large pharmaceutical companies to co-develop drug R&D projects," commented a senior scientist from MedAI. For further reading see AI in Medical Diagnostics 2020-2030: Image Recognition, Players, Clinical Applications, Forecasts.
The three drug discovery platforms built by MedAI are:
Artificial Intelligence Drug Discovery (AIDD) platform is constructed for the purpose of addressing two of the key bottlenecks in drug discovery: first, previously intractable therapeutic targets may become amenable to drug discovery; secondly, medicinal chemistry will be informed by both functional and structural data, maximizing chance of success. Overall speaking, by using AIDD platform, chances are that potential therapeutic drugs can be discovered.
Computer aided drug design (CADD) is a powerful technique that enjoys a reputation in facilitating drug design process and minimizing time and costs. MedAI's CADD platform applies computational software and chemistry simulation techniques to help identify novel hits or leads against selected therapeutic targets, as well as to support medicinal chemistry and lead optimization programs.
Experimental Validation Platform
Via the use of experimental validation platform, faster hit or lead discovery has been made possible. Also, the large-scale molecule exploration and evaluation, accurate property prediction and validation as well as integrated data management and visualization can all be easily realized at lower cost.
For more information about MedAI's three integrated platforms, please visit https://aimed.protheragen.com/platform.html.
Owing to the unparalleled expertise of a group of scientists, structural biologists, medical chemists, and machine learning experts, MedAI provides AI solutions to the pharma and biotechnology companies to enable streamlined R&D efforts. Its CADD Platform, AIDD Platform, Experimental Validation Platform have proved effects in helping researchers more efficiently and wisely make choices in drug discovery and development attempts. MedAI has already seen several successful use cases via cooperation with big pharma and institutions.
Source AI & Medicine
Top image: Pixabay